Celgene gets clearance for $9Billion Juno acquisition, strengthens its hematology global reach
February 21, 2018Celgene expects the transaction for Juno Therapeutics shares, to close in the first quarter of 2018. The company has said Wednesday that the applicable waiting period for all issued and outstanding shares of common stock of Juno for $87.00 per share, expired on Tuesday noon.
The expiration of the HSR waiting period satisfies one of the conditions to the closing of the pending acquisition, which remains subject to other customary closing conditions, the company said in its press release.
The tender offer is scheduled to expire at midnight ET on March 2, 2018, unless extended or earlier terminated.
The two companies announced this acquisition late January saying approximately $9 billion will be involved in the transaction.
Juno’s advanced cellular immunotherapy portfolio and research capabilities strengthen Celgene’s global leadership in hematology and adds new drivers for growth beyond 2020,” Mark J. Alles, Celgene’s Chief Executive Officer, said in January.
